Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | RAD52 | P43351 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070747 | 0.87 | MPO (0.57) | MPOKDM4ELMNAPKMMAPT | |
| SCHEMBL4080549 | 0.84 | KDM4E (0.59) | MPOKDM4ELMNAPKMMAPT | |
| SCHEMBL26568017 | 0.80 | KDM4E (0.66) | MPOKDM4ELMNAPKMMAPT | |
| SCHEMBL5457696 | 0.80 | RAD52 (0.65) | MPOKDM4ELMNAPKMMAPT | |
| SCHEMBL26568771 | 0.77 | ALDH1A1 (0.79) | KDM4ELMNAPKMMAPTNPC1 | |
| SCHEMBL26116157 | 0.77 | KDM4E (0.75) | KDM4ELMNAPKMMAPTNPC1 | |
| SCHEMBL26568020 | 0.76 | KDM4E (0.65) | MPOKDM4ELMNAPKMMAPT | |
| SCHEMBL26569399 | 0.74 | KDM4E (0.58) | MPOKDM4ELMNAPKMMAPT | |
| SCHEMBL4079401 | 0.73 | MPO (0.82) | MPOKDM4ELMNAPKMMAPT | |
| SCHEMBL30593620 | 0.71 | ALDH1A1 (0.71) | KDM4ELMNAPKMMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | claimed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | claimed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | claimed |
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | disclosed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | ABCG2, ATP5ME, ATP5MG | MPO 1056/4885KDM4E 2403/4885LMNA 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.